- Home
- USAU vs OBIO Comparison
USAU vs OBIO Comparison
Compare USAU & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | OBIO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 246.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | USAU | OBIO |
|---|---|---|
| Price | $14.14 | $4.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.83 | $14.25 |
| AVG Volume (30 Days) | ★ 270.3K | 219.9K |
| Earning Date | 03-16-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | $17,402,000.00 | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $7.38 | $2.20 |
| 52 Week High | $23.72 | $5.42 |
Technical Indicators
Market Signals| Indicator | USAU | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 43.99 |
| Support Level | $12.06 | $4.02 |
| Resistance Level | $14.39 | $4.88 |
| Average True Range (ATR) | 0.85 | 0.29 |
| MACD | -0.29 | -0.03 |
| Stochastic Oscillator | 10.14 | 16.22 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.